AMPH vs. ACLX, KYMR, PTGX, CRNX, ZLAB, AKRO, ACAD, AAPG, MIRM, and LNTH
Should you be buying Amphastar Pharmaceuticals stock or one of its competitors? The main competitors of Amphastar Pharmaceuticals include Arcellx (ACLX), Kymera Therapeutics (KYMR), Protagonist Therapeutics (PTGX), Crinetics Pharmaceuticals (CRNX), Zai Lab (ZLAB), Akero Therapeutics (AKRO), ACADIA Pharmaceuticals (ACAD), Ascentage Pharma Group International (AAPG), Mirum Pharmaceuticals (MIRM), and Lantheus (LNTH). These companies are all part of the "pharmaceutical products" industry.
Amphastar Pharmaceuticals vs. Its Competitors
Arcellx (NASDAQ:ACLX) and Amphastar Pharmaceuticals (NASDAQ:AMPH) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and earnings.
96.0% of Arcellx shares are held by institutional investors. Comparatively, 65.1% of Amphastar Pharmaceuticals shares are held by institutional investors. 8.4% of Arcellx shares are held by insiders. Comparatively, 27.5% of Amphastar Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Arcellx had 5 more articles in the media than Amphastar Pharmaceuticals. MarketBeat recorded 8 mentions for Arcellx and 3 mentions for Amphastar Pharmaceuticals. Amphastar Pharmaceuticals' average media sentiment score of 1.13 beat Arcellx's score of 0.04 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the news media.
Amphastar Pharmaceuticals has higher revenue and earnings than Arcellx. Arcellx is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Arcellx presently has a consensus price target of $112.69, suggesting a potential upside of 22.00%. Amphastar Pharmaceuticals has a consensus price target of $31.60, suggesting a potential upside of 36.56%. Given Amphastar Pharmaceuticals' higher probable upside, analysts clearly believe Amphastar Pharmaceuticals is more favorable than Arcellx.
Amphastar Pharmaceuticals has a net margin of 18.64% compared to Arcellx's net margin of -329.93%. Amphastar Pharmaceuticals' return on equity of 20.76% beat Arcellx's return on equity.
Arcellx has a beta of 0.31, meaning that its stock price is 69% less volatile than the S&P 500. Comparatively, Amphastar Pharmaceuticals has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500.
Summary
Amphastar Pharmaceuticals beats Arcellx on 11 of the 17 factors compared between the two stocks.
Get Amphastar Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for AMPH and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding AMPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Amphastar Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:AMPH) was last updated on 10/16/2025 by MarketBeat.com Staff
